Norwegian-registered foreign company · Oslo
ASTELLAS PHARMA NUF
ActiveActivities of agents involved in the wholesale of other particular products (46.180)
The life line 2025–2026
Operating revenue per year, with recorded events above. As a table
Operating revenue 2026: NOK 21.7m.
Sources: the Register of Company Accounts (company accounts), fetched 1 Nov 2026; the Brønnøysund Register Centre. Each event has the colour of the section it is in.
In brief
ASTELLAS PHARMA NUF is a norwegian-registered foreign company in Oslo, in the industry activities of agents involved in the wholesale of other particular products. The chief executive is Mark Andree Dekker. In 2026 the company had NOK 21.7m in operating revenue and a net profit of NOK −1.7m.
Put together by Intelligo from the sections below; each figure stands with its source where it belongs.
Overview
§ 01 Latest changes
4 changes, latest 16 Oct 2026
- Annual accounts filed 2025 → 2026
- Godkjent årsregnskap
- Endring av daglig leder
- Endring av forretningsadresse
Source: the Brønnøysund Register Centre and Intelligo's own observations, fetched 15 Nov 2026 · All events →
Overview
§ 02 Worth knowing
None registered
None of the rules apply.The rules are fixed: bankruptcy, missing annual accounts, three years of losses, negative equity and the like. Checked 15 Nov 2026.
Overview
§ 03 Key figures
Revenue NOK 21.7m in 2026
Revenue
NOK 21.7m
−37.2% from 2025
20242026
Operating profit
NOK −2.1m
−255.9% from 2025
20242026
Net profit
NOK −1.7m
−277.8% from 2025
20242026
Equity
—
— from 2025
20242026
Source: the Register of Company Accounts, read 1 Nov 2026 · The full accounts →
Finances
§ 04 Where the money comes from and goes
Financial year 2026
Of every krone of operating revenue in 2026:
- Operating costs 110%
Costs exceeded revenue: the operating result was NOK −2.1m.
Source: the Register of Company Accounts, read 1 Nov 2026
Finances
§ 05 Financial health
Financial year 2026
- ASTELLAS PHARMA NUF, 2026
- Industry median, assumed: NOK 52.8m · 4.8% · −0.4%
Source: the Register of Company Accounts, read 1 Nov 2026. The median is derived by Intelligo from 165 companies in industry division 46 (Wholesale trade), not stated by the source.
Finances
§ 06 Accounts
2 years, latest 2026
| NOK 1,000 | 2025–26 | 2026 | 2025 |
|---|---|---|---|
| Operating revenue | 21,691 | 34,545 | |
| Operating profit | −2,128 | 1,365 | |
| Profit before tax | −1,914 | 1,578 | |
| Net profit | −1,744 | 981 | |
| Total assets | 7,558 | 8,071 | |
| Equity | — | 0 | |
| Liabilities | 7,558 | 8,071 |
Source: the Register of Company Accounts, read 1 Nov 2026 · All 2 years →
Management and ownership
§ 07 Officers
5 officers now
- ASTELLAS PHARMA A/SDetails of the company in its home country
- ERNST & YOUNG ASAuditor
- ASPIA NORGE ASAccountant
- Mark Andree DekkerChief executive since 2025
- ENORA ASAccountant
Source: the Brønnøysund Register Centre, read 23 Oct 2026 · All 5 roles, former ones too →
Management and ownership
§ 08 Signature, procuration and authorisations
None registered
No signature or procuration registered.The Register of Business Enterprises has no provision for the company. Checked 15 Nov 2026.
Management and ownership
§ 09 Owners
None registered
No owners registered.The Tax Administration's shareholder register covers limited companies and has no owners for this business. Checked 15 Nov 2026.
Management and ownership
§ 10 Group
None registered
Not a group.No subsidiaries in the shareholder register, and no group accounts. Checked 15 Nov 2026.
Management and ownership
§ 11 Portfolio
None registered
No holdings registered.The shareholder register has no shares held by the company. Checked 15 Nov 2026.
Management and ownership
§ 12 Network
None registered
No connections.Nobody with a role here has roles in other companies. Checked 15 Nov 2026.
Events and registers
§ 13 Events
27 since 2015
Events per year
20152026
Since 2015: 39 announcements, 1 register change and 1 tender won. Most happened in 2015 and 2025.
Source: the announcements of the Brønnøysund Register Centre, the Tax Administration's Register of Shareholders, Doffin, TED and NAV, read 1 Nov 2026. Register changes are Intelligo's own observations. · All 27 events →
Events and registers
§ 14 Notices
39, latest 15 Oct 2026
- Godkjente årsregnskap
- Daglig leder
- Forretningsadresse
Source: The Brønnøysund Register Centre's announcements ↗, read 1 Nov 2026 · All 39 →
Events and registers
§ 15 Charges
Not fetched yet
Events and registers
§ 16 Other registers
Found in 3 of 7
- The Central Coordinating RegisterRegistered 20 Feb 1995
- VATRegistered
- The Register of Business EnterprisesRegistered 6 Jan 1994
- The Cleaning RegisterNot registered
- The Register of Staffing AgenciesNot registered
- Smiley scheme, the Norwegian Food Safety AuthorityNot registered
- The Financial Supervisory Authority's licence registerNot registered
Source: the Brønnøysund Register Centre, the Labour Inspection Authority, the Food Safety Authority and the Financial Supervisory Authority, each on its own, fetched 15 Nov 2026
Market
§ 17 Tenders
1 tender
- 2025
- Won
- Lost
| Awarded | Contract | Buyer | Outcome |
|---|---|---|---|
| May 2025 | Intensjonskunngjøring: Avtale Xtandi (enzalutamid) | SYKEHUSINNKJØP HF | Won |
Source: Doffin and TED, read 10 Jul 2026. · All 1 tenders →
Market
§ 18 Vacancies
None registered
No vacancies.No open ads at NAV. Checked 15 Nov 2026.
Market
§ 19 Competitors
Industry code 46.180
The companies most like it:
The selection is Intelligo's, not stated by the source: companies met in tenders and winners of tenders of the same kind, otherwise the same industry code, nearest in place and size. Source: the Brønnøysund Register Centre, Doffin and TED, fetched 15 Nov 2026 · All competitors → · Largest in the industry →
Last
§ 20 Questions and answers
4 questions
- Who is the chief executive of ASTELLAS PHARMA NUF?
Mark Andree Dekker, since 2025. § 07 - What was the revenue in 2026?
NOK 21.7m in the company. § 06 - Who is the auditor?
ERNST & YOUNG AS. § 07 - Where is ASTELLAS PHARMA NUF based?
C. J. Hambros plass 2, 0164 Oslo.
The answers come from the sections linked to, with their sources.